Introduction
============

Prostate cancer (PCa) is a heterogeneous and multifactorial pathology that presents itself in the form of indolent or very aggressive tumors and is a significant source of morbidity in the male population. In 2018, 1.3 million new cases were estimated and 359,000 associated deaths worldwide, however, the mortality rates do not follow the incidence rates. In certain countries, PCa still presents an elevated degree of mortality ([@B37]; [@B2]).

The most commonly utilized methods for the prognosis of this type of tumor are the TNM classification for staging, used in combination with the Gleason/tumor grade and prostate-specific antigen (PSA) level ([@B3]). However, the clinical applications of these indicators are limited. The American Urological Association encourages the identification of novel markers that can identify men at a greater risk of developing and progressing in the disease ([@B4]). Studies have increasingly associated single-nucleotide polymorphisms (SNPs) with various diseases, resulting in SNPs being progressively utilized as markers associated with cancer, including PCa. Consequently, SNPs have received considerable attention for use as prognostic indicators in pre and post-treatment PCa patients ([@B35]).

In recent decades, different SNPs have been associated with important cellular pathways, including the PI3K/PTEN/AKT signaling pathway ([@B17]), androgen action pathway ([@B34]), and fatty acid metabolization pathway ([@B20]). In this manner, they are related to the development of prostate adenocarcinoma.

The *PTEN* gene is a tumor suppressor with dual specificity. The principal substrate is phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The protein PTEN acts as an antagonist on the PI3K/AKT pathway by maintaining low PIP3 levels. The greater the concentration of PIP3, the greater the signaling of the PI3K/AKT pathway, which promotes inhibition of the cellular cycle, migration, metastasis, and apoptosis. The occurrence of loss of *PTEN* gene function is greater in aggressive metastatic disease, meaning that it can be used as a biomarker for prognosis in distinguishing indolent tumors from those that are aggressive ([@B7]; [@B17]; [@B46]).

Meanwhile, the *PI3K* gene is a proto-oncogene; the corresponding protein phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2), converting it into PIP3. Given the complexity of this intracellular signaling cascade and its association with the development of PCa, it is important to delineate the role of polymorphism in this gene with respect to prognosis and susceptibility ([@B41]).

In addition, the *AKT1* gene is a proto-oncogene whose corresponding protein regulates events downstream in the PI3K signal transduction pathway. This protein plays an important role in inhibition of cellular viability, proliferation, differentiation, and apoptosis ([@B44]). The overexpression of this gene is related to different types of cancer, including the progression and biochemical recurrence of prostate tumors ([@B10]; [@B22]).

Finally, the *AR* gene encodes the androgen receptor, a nuclear transcription factor that is involved in the development, maintenance, and regulation of the male reproductive system ([@B10]). Mutations in *AR* are associated with a series of diseases, ranging from androgen insensitivity syndrome to prostate cancer ([@B13]). Among the mutations in this gene, SNPs are the most frequent type of alteration. Even a simple change in amino acids can result in either an increase in expression or a loss in gene function ([@B40]; [@B48]).

The peroxisomal and mitochondrial enzyme Alpha-methylacyl-CoA racemase (AMACR) is coded by the gene *P504S* (*AMACR*) and is involved in the biosynthesis and beta-oxidation of dietary fatty acids ([@B25]). Fatty acid metabolism represents a key process that influences different pathways and cellular characteristics, including cellular signaling, energetic processing, and membrane fluidity, among others ([@B27]).

Considering that the majority of cases of PCa are indolent, markers are needed that aid in classifying the degree of tumor aggressiveness and in providing individual treatment, in line with the genetic characteristics of each patient. In this sense, a case-control study was performed that evaluated the possible relationship between polymorphic variants of the genes *PTEN, PI3K, AKT1, P504S (AMACR)*, and *AR* and prostate cancer susceptibility. In addition, data from the association study were correlated with the clinical parameters of the patients and the histopathological parameters of the tumors, with the aim of establishing prognostic molecular markers.

Subjects and Methods
====================

Study cohorts
-------------

In total, 554 male individuals were studied, with 277 serving as a control, free of PCa with a prostate-specific antigen (PSA) value lower than 2 ng/mL, and with 277 patients diagnosed with PCa, as confirmed by histopathological analysis. Individuals were excluded if they had been submitted to radiotherapy and/or chemotherapy. The patients were paired with controls on a 1:1 basis, maintaining age (± 5 years), ancestry (European and African), and alcohol and tobacco use consistent between pairs. Peripheral blood samples of the patients and controls were collected from 2006 to 2015 at CISMEPAR (Consórcio Intermunicipal de Saúde do Médio Paranapanema), the Irmandade Santa Casa de Londrina, the State University of Londrina, and the Cancer Hospital of Londrina.

Disease stage was determined by pathology findings, pelvic computed tomography, or magnetic resonance image. Tumor staging was determined according to criteria established by the Union for International Cancer Control (2009) tumor-node-metastasis (TNM) classification system. Pathologic grading was recorded as the Gleason score and was further classified into 2 groups: Gleason score 3--7 (3+4) and Gleason 7(4+3)--10.

The patients and controls were volunteers and written informed consent was obtained from each participant that responded to the questionnaire, which was based on [@B5]. The study was approved by the Ethics Committee Involving Research on Human Beings of the State University of Londrina (CEPE/UEL 176/2013).

Extraction of genomic DNA
-------------------------

Peripheral blood was collected in tubes of EDTA (ethylenediaminetetraacetic acid), from which DNA was extracted using the High Pure PCR Template Preparation (Cat. 11796828001; Roche; IN, USA) commercial kit, following the manufacturer\'s instructions. DNA quantification was carried out via spectrophotometry, using a Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Absorption was measured at 260/280 nm in order to determine the purity of the nucleic acid, with samples with a ratio between 1.8 and 2.0 being considered pure.

Genotyping
----------

Each gene selected for this study had one defined SNP chosen from the public Database of Single Nucleotide Polymorphisms (NCBI, 2016): *PTEN* (rs2735343), *AKT* (rs2494750), *PI3K* (rs2699887), *AR* (rs17302090), and *P504S (AMACR)* (rs3195676).

The genotypes were determined via real-time PCR molecular analysis using a hydrolysis probe (TaqMan System, Applied Biosystems, Foster City, CA, USA). The reactions contained the genotyping master mix (Applied Biosystems), 5 ng/mL of DNA, and the specific probe for each gene. Reagent quantities and cycling were carried out according to the manufacturer\'s specifications.

Statistical analysis
--------------------

The χ^2^ test was used to determine if the genotype distributions were in a Hardy-Weinberg equilibrium. Allele frequency was calculated as \[1(h + 2H)\]/2 N, where h represents the heterozygous genotype, H is the homozygous genotype, and N is the sample size for each population.

First, the association between the following parameters: family history of cancer, family history of PCa, vasectomy, occupational exposure to agrochemicals, level of schooling, and consumption of red meat was determined through univariate logistic regression analysis, aiming to assess the impact of these variables on cancer risk. The association between the genotypes and cancer risk was also run by univariate logistic regression analysis.

Subsequently, multivariate logistic regression analyses were performed aiming to assess the impact of the studied SNPs on PCa risk. Variables that had a *p*-value ≤ 0.05 were included in the model: family history of cancer, family history of PCa, and level of schooling, avoiding possible bias in the analysis.

The different genotypes were evaluated with respect to histopathological parameters (Gleason score, bilaterality, seminal vesicle invasion, perineural invasion, lymphatic invasion, and extracapsular extension) and a clinical parameter (PSA).

Results are expressed as Odds Ratio (OR) with a confidence interval of 95% (CI95%) and assumed statistically significant for a *p* ≤ 0.05. Analyses were performed using SPSS 20.0 (IBM, Armonk, NY, USA).

Results
=======

The total sample was composed of 554 men, of which 85.6% were of European and 14.4% of African descent. The average age of the patients was 65.38 ± 7.18 years, while that of the control was 63.65 ± 8.21 years. In both groups, 68 individuals (24.5%) were tobacco users, while 141 individuals (50.9%) consumed alcohol.

Genotype frequencies were in Hardy-Weinberg equilibrium within a significance level of 5%. The univariate statistical analysis revealed significant differences between patients and controls with respect to a family history of cancer (58.8% of patients had at least one first-degree relative who was affected), a family history of PCa, and level of schooling. Other analyzed parameters, such as vasectomy, occupational exposure to agrochemicals, and red meat consumption, did not present statistically significant differences between patients and controls ([Table 1](#t1){ref-type="table"}).

###### Demographic and clinical characteristics of prostate cancer patients and cancer-free controls.

  Characteristics                                                                 Case   Controls   *P*             
  ---------------------------------------- -------------------------------------- ------ ---------- ----- --------- --------------------------------------------
  Family history of cancer                 No                                     114    (41.2)     159   (57.4)    
                                           Yes                                    163    (58.8)     118   (42.6)    **0.000** [\*](#TFN2){ref-type="table-fn"}
                                           Total                                  277    (100.0)    277   (100.0)   
  Family history of PCa                    No                                     101    (65.2)     86    (77.5)    
                                           Yes                                    54     (34.8)     25    (22.5)    **0.031** [\*](#TFN2){ref-type="table-fn"}
                                           Total[a](#TFN1){ref-type="table-fn"}   155    (100.0)    111   (100.0)   
  Vasectomy                                No                                     270    (98.5)     265   (97.4)    
                                           Yes                                    4      (1.5)      7     (2.6)     0.361
                                           Total[a](#TFN1){ref-type="table-fn"}   274    (100.0)    272   (100.0)   
  Occupational exposure to agrochemicals   No                                     115    (41.5)     134   (48.4)    
                                           Yes                                    162    (58.5)     143   (51.6)    0.105
                                           Total[a](#TFN1){ref-type="table-fn"}   277    (100.0)    277   (100.0)   
  Level of schooling                       S                                      47     (17.0)     45    (16.2)    
                                           P                                      167    (60.3)     20    (72.6)    0.327
                                           N                                      61     (22.0)     27    (9.7)     **0.013** [\*](#TFN2){ref-type="table-fn"}
                                           Total[a](#TFN1){ref-type="table-fn"}   275    (100.0)    92    (100.0)   
  Consumption of red meat                  No                                     9      (3.2)      8     (2.9)     
                                           Yes (1-4)                              151    (54.5)     137   (49.5)    0.967
                                           Yes (5-7)                              117    (42.2)     132   (47.7)    0.635
                                           Total                                  277    (100.0)    277   (100.0)   

It was not possible to evaluate all patients and controls. Level of schooling - S: secondary school complete or higher; P: primary school incomplete to secondary school incomplete; N: no formal schooling. Consumption of red meat - 1-4: 1 to 4 times per week; 5-7: 5 to 7 times per week.

significant *p*-values are in bold.

The comparison of the genotypic variants and allele frequencies of each of the genes studied showed no statistically significant differences between patients with PCa and controls. A multivariate statistical analysis adjusted for the determined risk factors indicated a protecting effect for genotypes CG and CG + GG for the rs2494750 *AKT1*gene ([Table 2](#t2){ref-type="table"}). A multivariate analysis of the paired genes (Table S1) showed that the genotypes *AKT1* (CG) + *AR* (A) provided protection against PCa ([Table 3](#t3){ref-type="table"}).

###### Univariate and multivariate regression analysis of genotypes and allele of *PTEN, AKT1, PI3K, AR*, and *AMACR* genes in controls and patients with prostate cancer.

  Gene               Genotypes   Case N (%)   Control N (%)   Not adjusted           Adjusted                                                            
  ------------------ ----------- ------------ --------------- ---------------------- -------------------------------------------- ---------------------- --------------------------------------------
  *PTEN*             CC          55 (19.9)    36 (13.0)       Reference                                                           Reference              
  rs2735343          CG          115 (41.5)   143 (51.6)      **0.53 (0.32-0.86)**   **0.010** [\*](#TFN4){ref-type="table-fn"}   0.44 (0.17-1.15)       0.092
                     GG          107 (38.6)   98 (35.4)       0.72 (0.43-1.18)       0.189                                        0.58 (0.22-1.54)       0.275
  Dominant model                                                                                                                                         
                     CC          55 (19.9)    36 (13.0)       Reference                                                           Reference              
                     CG+GG       222 (80.1)   241 (87.0)      **0.60 (0.38-0.95)**   **0.030** [\*](#TFN4){ref-type="table-fn"}   0.50 (0.21-1.20)       0.121
  Recessive model                                                                                                                                        
                     CC+CG       170 (61.4)   179 (64.6)      Reference                                                           Reference              
                     GG          107 (38.6)   98 (35.4)       1.15 (0.81-1.62)       0.428                                        1.08 (0.59-1.98)       0.800
  Allele frequency                                                                                                                                       
                     C           225 (40.6)   215 (38.8)      Reference                                                                                  
                     G           329 (59.4)   339 (61.2)      0.93 (0.73-1.18)       0.539                                                               
                                                                                                                                                         
  *PI3K*             GG          172 (62.1)   177 (63.9)      Reference                                                           Reference              
  rs2699887          GA          90 (32.5)    87 (31.4)       1.07 (0.74-1.53)       0.735                                        0.95 (0.51-1.75)       0.859
                     AA          15 (5.4)     13 (4.7)        1.18 (0.56-2.48)       0.663                                        1.50 (0.36-6.24)       0.579
  Dominant model                                                                                                                                         
                     GG          172 (62.1)   177 (63.9)      Reference                                                           Reference              
                     GA+AA       105 (37.9)   100 (36.1)      1.08 (0.77-1.53)       0.660                                        1.00 (0.55-1.81)       0.999
  Recessive model                                                                                                                                        
                     GA+GG       262 (94.6)   264 (95.3)      Reference                                                           Reference              
                     AA          15 (5.4)     13 (4.7)        1.16 (0.54-2.49)       0.698                                        1.56 (0.81-3.02)       0.188
  Allele frequency                                                                                                                                       
                     G           433 (78.2)   441 (79.6)      Reference                                                                                  
                     A           121 (21.8)   113 (20.4)      1.09 (0.82-1.46)       0.556                                                               
  *AKT1*             CC          210 (75.8)   203 (73.2)      Reference                                                           Reference              
  rs2494750          CG          66 (23.8)    73 (26.4)       0.87 (0.60-1.28)       0.493                                        **0.75 (0.57-0.99)**   **0.045** [\*](#TFN4){ref-type="table-fn"}
                     GG          1 (0.4)      1 (0.4)         0.97 (0.06-15.56)      0.981                                        --                     --
  Dominant model                                                                                                                                         
                     CC          210 (75.8)   203 (73.2)      Reference                                                           Reference              
                     CG+GG       67 (24.2)    74 (26.7)       0.88 (0.60-1.28)       0.495                                        **0.76 (0.58-0.99)**   **0.044** [\*](#TFN4){ref-type="table-fn"}
  Recessive model                                                                                                                                        
                     CG+CC       276 (99.6)   276 (99.6)      Reference                                                           Reference              
                     GG          1 (0.4)      1 (0.4)         1.00 (0.06-16.07)      1.000                                        --                     --
  Allele frequency                                                                                                                                       
                     C           486 (87.7)   479 (86.5)      Reference                                                                                  
                     G           68 (12.3)    75 (13.5)       0.89 (0.63-1.27)       0.531                                                               
                                                                                                                                                         
  *AMACR*            GG          107 (38.7)   96 (34.7)       Reference                                                           Reference              
  rs3195676          GA          125 (45.1)   118 (42.6)      0.95 (0.65-1.38)       0.789                                        1.02 (0.54-1.94)       0.948
                     AA          45 (16.2)    63 (22.7)       0.64 (0.40-1.03)       0.064                                        0.53 (0.24-1.19)       0.124
  Dominant model                                                                                                                                         
                     GG          107 (38.6)   96 (34.7)       Reference                                                           Reference              
                     GA+AA       170 (61.4)   181 (65.3)      0.84 (0.60-1.19)       0.332                                        0.84 (0.45-1.56)       0.575
  Recessive model                                                                                                                                        
                     GA+GG       232 (83.8)   214 (77.3)      Reference                                                           Reference              
                     AA          45 (16.2)    63 (22.7)       0.66 (0.43-1.01)       0.054                                        0.54 (0.27-1.04)       0.067
  Allele frequency                                                                                                                                       
                     G           339 (61.2)   310 (56.0)      Reference                                                                                  
                     A           215 (38.8)   244 (44.0)      0.81 (0.63-1.02)       0.077                                                               
                                                                                                                                                         
  *AR*               G           99 (35.7)    88 (31.8)       Reference                                                           Reference              
  rs17302090         A           178 (64.3)   189 (68.2)      0.84 (0.59-1.19)       0.323                                        0.81 (0.49-1.35)       0.422

OR (CI95%): odds ratio value, with a confidence interval of 95%. Adjusted for family history of cancer, family history of prostate cancer, and schooling.

Statistically significant value, *p*\< 0.05; in bold.

###### Univariate and multivariate logistic regression analysis of the association between *AKT1* and *AR* genes in prostate cancer patients and controls.

  Gene         Genotypes   Cases N (%)   Controls N (%)   Not adjusted        Adjusted                          
  ------------ ----------- ------------- ---------------- ------------------- ---------- ---------------------- --------------------------------------------
  *AKT1*       CC+G        71 (25.6)     66 (23.8)        Reference                      Reference              
  rs2494750    CC+A        139 (50.2)    137 (49.5)       0.94(0.63-1.42)     0.780      1.01 (0.62-1.64)       0.965
  **+**        CG+G        28 (10.1)     22 (7.9)         1.83 (0.62-2.27)    0.613      1.28 (0.62-2.66)       0.505
  *AR*         CG+A        38 (13.7)     51 (18.4)        0.69 (0.41-1.19)    0.180      **0.50 (0.26-0.97)**   **0.041** [\*](#TFN6){ref-type="table-fn"}
  rs17302090   GG+G        0 (0.0)       0 (0.0)          0.93 (0.06-15.17)   0.959      --                     --
               GG+A        1 (0.4)       1 (0.4)          --                  --         --                     --

OR (CI95%): odds ratio value, with a confidence interval of 95%. Adjusted for family history of cancer, family history of prostate cancer, and schooling.

Statistically significant value, *p*\< 0.05.

[Table 4](#t4){ref-type="table"} presents the clinical and histopathological parameters obtained from the patient histories. In total, 147 patients presented a PSA level of 4.1-10.0 ng/mL, 115 patients presented a level greater than 10.0 ng/mL, and only 10 had a level below 4.0 ng/mL. Meanwhile, 133 patients had Gleason scores of 3-6, 117 patients had a score of 7, and only 25 had scores of 8-10. Tumor bilaterality was observed in 137 patients. According to the TNM system, 154 cases had tumors in stage T2, while 101were in stages T3 and T4. The other parameters were absent for the majority of the patients.

###### Analysis of PSA levels of prostate cancer patients and histopathological characteristics of the tumors.

  Parameters                 Categories                              N     \%
  -------------------------- --------------------------------------- ----- -------
  PSA level                  0.0 - 4.0                               10    3.7
  (ng/mL)                    4.1 - 10.0                              147   54.0
                             \> 10.1                                 115   42.3
                             Total[\*](#TFN7){ref-type="table-fn"}   272   100.0
  Gleason Score              3-6                                     133   48.4
                             7                                       117   42.5
                             8-10                                    25    9.1
                             Total[\*](#TFN7){ref-type="table-fn"}   275   100.0
  Extracapsular extension    Presence                                97    37.7
                             Absence                                 160   62.3
                             Total[\*](#TFN7){ref-type="table-fn"}   257   100.0
  Seminal vesicle invasion   Presence                                32    12.5
                             Absence                                 225   87.5
                             Total[\*](#TFN7){ref-type="table-fn"}   257   100.0
  Perineural invasion        Presence                                42    16.3
                             Absence                                 215   83.7
                             Total[\*](#TFN7){ref-type="table-fn"}   257   100.0
  Bilaterality               Presence                                137   53.1
                             Absence                                 121   46.9
                             Total[\*](#TFN7){ref-type="table-fn"}   258   100.0
  Lymphatic invasion         Presence                                6     2.5
                             Absence                                 232   97.5
                             Total[\*](#TFN7){ref-type="table-fn"}   238   100.0
  TNM Staging                T2                                      154   60.4
                             T3 and T4                               101   39.6
                             Total[\*](#TFN7){ref-type="table-fn"}   255   100.0

It was not possible to evaluate the parameters for all 277 patients.

The genotypes of the five SNPs were evaluated for their relationship with the various histopathological and clinical parameters (Table S2). A comparison of the heterozygous and/or polymorphic genotypes with the prevalent genotypes indicated that only the isolated GA and GA+AA genotypes of the *AMACR* gene protected against seminal vesicle invasion ([Table 5](#t5){ref-type="table"}).

###### Univariate regression analysis between genotypes of *PTEN, AKT, PI3K, AR*, and *AMACR* genes with clinicopathological features in prostate cancer patients.

  Histopathological parameters   Genes SNP_ID   Genotypes   Present N (%)   Absent N (%)   OR (CI95%)              *p*
  ------------------------------ -------------- ----------- --------------- -------------- ----------------------- -------------
  Seminal vesicle                *AMACR*        GG          19 (59.4)       82 (36.4)      Reference               
  Invasion                       rs3591676      GA          8 (25.0)        105 (46.7)     **0.33 (0.14-0.80)**    **0.013\***
  (n = 257)                                     AA          5 (15.6)        38 (16.9)      0.57 (0.20-1.64)        0.294
                                                GA+AA       13 (40.6)       143 (63.6)     **0.39 (0.18-0.84)**    **0.015\***
                                                                                                                   
                                 *AKT1*         CC+G        14 (43.8)       53 (23.6)      Reference               
                                 rs2494750      CC+A        13 (40.6)       115 (51.1)     **0.43 (0.19-0.97)**    **0.043\***
                                 **+**          CG+G        2 (6.3)         25 (11.1)      0.30 (0.06-1.44)        0.132
                                 *AR*           CG+A        3 (9.4)         31 (13.8)      0.37 (0.10-1.38)        0.137
                                 rs17302090     GG+A        0 (0.0)         1 (0.4)        --                      --
                                                                                                                   
                                 *AKT1*         CC+GG       16 (50.0)       57 (25.3)      Reference               
                                 rs2494750      CC+GA       7 (21.9)        81 (36.0)      **0.31 (0.12-0.80)**    **0.015\***
                                 **+**          CC+AA       4 (12.5)        30 (13.3)      0.48 (0.15-1.55)        0.217
                                 *AMACR*        CG+GG       3 (9.4)         25 (11.1)      0.43 (0.11-1.60)        0.207
                                 rs3195676      CG+GA       1 (3.1)         23 (10.2)      0.16 (0.02-1.24)        0.078
                                                CG+AA       1 (3.1)         8 (3.6)        0.45 (0.05-3.83)        0.461
                                                GG+GA       0 (0.0)         1 (0.4)        --                      --
                                                                                                                   
  Bilaterality                   *AKT1*         CC+G        43 (31.4)       24 (19.8)      Reference               
  (n = 258)                      rs2494750      CC+A        63 (46.0)       66 (54.5)      **0.53 (0.29-0.98)**    0.042\*
                                 **+**          CG+G        13 (9.5)        14 (11.6)      0.52 (0.21-1.28)        0.155
                                 *AR*           CG+A        17 (12.4)       17 (14.0)      0.56 (0.24-1.29)        0.172
                                 rs17302090     GG+G        0 (0.0)         0 (0.0)        --                      --
                                                GG+A        1 (0.7)         0 (0.0)        --                      
                                                                                                                   
                                 *PI3K*         GG+G        38 (27.7)       21 (17.4)      Reference               
                                 rs2699887      GG+A        47 (34.3)       52 (43.0)      **0.50 (0.26-0.97)**    0.040\*
                                 **+**          GA+G        18 (13.1)       16 (13.2)      0.62 (0.26-1.47)        0.278
                                 *AR*           GA+A        26 (19.0)       25 (20.7)      0.58 (0.27-1.24)        0.156
                                 rs17302090     AA+G        0 (0.0)         1 (0.8)        --                      --
                                                AA+A        8 (5.8)         6 (5.0)        0.74 (0.23-2.41)        0.614
  Extracapsular                  *PTEN*         CC+GG       6 (6.2)         22 (13.8)      Reference               
  Extension                      rs2735343      CC+GA       6 (6.2)         11 (6.9)       2.00 (0.52-7.66)        0.312
  (n = 257)                      **+**          CC+AA       3 (3.1)         3 (1.9)        3.67 (0.58-23.03)       0.166
                                 *AMACR*        CG+GG       16 (16.5)       19 (11.9)      **3.09 (1.01-9.48)**    **0.049\***
                                 rs3591676      CG+GA       20 (20.6)       30 (18.8)      2.44 (0.84-7.09)        0.100
                                                CG+AA       11 (11.3)       13 (8.1)       3.10 (0.93-10.39)       0.066
                                                GG+GG       15 (15.5)       23 (14.4)      2.39 (0.79-7.28)        0.125
                                                GG+GA       17 (17.5)       29 (18.1)      2.15 (0.73-6.35)        0.166
                                                GG+AA       3 (3.1)         10 (6.3)       1.10 (0.23-5.31)        0.906
                                                                                                                   
                                 *PTEN*         CC+G        5 (5.2)         21 (13.1)      Reference               
                                 rs2735343      CC+A        10 (10.3)       15 (9.4)       2.80 (0.79-9.89)        0.110
                                 **+**          CG+G        15 (15.5)       18 (11.3)      **3.50 (1.06-11.53)**   **0.039\***
                                 *AR*           CG+A        32 (33.0)       44 (27.5)      **3.06 (1.04-8.96)**    **0.042\***
                                 rs17302090     GG+G        14 (14.4)       21 (13.1)      2.80 (0.86-9.18)        0.089
                                                GG+A        21 (21.6)       41 (25.6)      2.15 (0.71-6.52)        0.175

OR (CI95%): Odds Ratio value, with a confidence interval of 95%.

Statistically significant value, *p*\< 0.05.

When the genotypes of different SNPs were compared, several statistically significant results were obtained. The following associations indicated protection for seminal vesicle invasion: *AKT1* (CC) *+ AR* (A) and *AKT1* (CC) + *AMACR* (GA). The associations that indicated protection for tumor bilaterality were: *AKT1* (CC) + *AR* (A) and *PI3K* (GG) + *AR* (A) ([Table 5](#t5){ref-type="table"}).

Finally, the following combinations of genotypes indicated a greater risk of extracapsular extension: *PTEN* (CG) + *AMACR* (GG), *PTEN* (CG) + *AR* (G), and *PTEN* (CG) + *AR* (A) ([Table 5](#t5){ref-type="table"}).

Discussion
==========

PCa is a heterogeneous pathology that currently has a lifetime possibility of detection of 19%, while the risk of death is just 8%. This discrepancy between incidence and mortality is attributed not just to treatment offered, but also to the increase in initial tumor detection and slow growth ([@B38]). Patients with slow-growing tumors could be exposed to unnecessary risks as a consequence of therapy. As such, currently, the greatest challenge with PCa is the identification of markers that can be used to classify tumors according to their potential for aggressive behavior and the recognition of patients that need specific therapy ([@B43]).

The rate of development of PCa varies substantially according to age ([@B36]), ancestry ([@B1]), and family history ([@B38]). In this study, a family history of cancer was a risk factor (*p* = 0.001). Patients with PCa in their family also presented greater susceptibility to developing prostatic neoplasia (*p* = 0.031). These findings demonstrate the high contribution of heredity in the development of this carcinoma. [@B6] demonstrated that, while there are inheritable sites that determine susceptibility to prostate cancer, there is not only one gene that alone determines susceptibility; the pathology of the disease involves a large number of genes, meaning that this illness is treated as being multifactorial.

Education is an indicator of socioeconomic status, and is inversely associated with the incidence of cancer in various organs; in general, the greater the level of schooling, the lower the risk of aggressive cancer ([@B29]). In the studied sample, the individuals without formal schooling presented twice the risk of PCa when compared to their respective controls. These data are consistent with [@B47], who stated that a higher degree of schooling offers greater comprehension of prostate health and, consequently, leads to individuals seeking out medical care. In this case, low patient schooling could lead to tumor diagnosis in more advanced stages and result in a higher mortality index.

The average patient age in this study was 65.38 ± 7.15 years, which corroborates the literature data that show that PCa is a disease of old age; the majority of cases of sporadic PCa are observed in men over the age of 65. This fact has been related to the accumulation of DNA damage ([@B31]).

PSA is a glycoprotein produced by prostate epithelial cells that does not constitute a specific cancer marker, given that it can be changed in other diseases of the prostate ([@B12]; [@B14]); furthermore, no exact value exists that can determine the presence of a malignant disease. The PSA values at the time of diagnosis determined in this study ranged from 1.5 to 933.9 ng/mL, confirming that the specificity of this marker for PCa is low. Given this characteristic, the U.S. Preventive Services Task Force, as well as various other health entities around the world, recommend not tracking PCa using PSA, given that despite appearing in many PCa cases, its correlation with mortality is minimal ([@B19]).

Considering the important role that SNPs play as biomarkers in various types of diseases, genes and SNPs that are candidates for PCa susceptibility and prognosis were chosen ([@B45]). These include PTEN/PI3K/AKT signaling pathway components, which are important regulators for growth, metabolism, cell cycle, DNA repair, and apoptosis inhibition ([@B50]).

The rs2735343 gene *PTEN*, studied herein is located in an intronic region. According to [@B17], it can influence splicing, protein expression, and, consequently, the regulation of the cell cycle and the risk of cancer. The aforementioned authors showed that carriers of the homozygous GG genotype, the same SNP evaluated in this study, presented a greater risk for esophageal squamous cell carcinoma (ESCC). This SNP was also considered by [@B28] as a factor of susceptibility for ESCC in patients that presented CG and GG genotypes. [@B39] performed a meta-analysis with different types of cancer, including PCa and the associated risk of cancer for carriers of the G allele in an Asian population. In this study, we did not find any association between the variants of this gene and susceptibility to PCa. Nonetheless, in all genotypic combinations in which we detected a greater risk of extracapsular extension, the G allele of the (rs2735343) *PTEN* gene was present ([Table 4](#t4){ref-type="table"}), which seems to confirm the above-cited hypotheses.

The heterozygous genotype (CG) in these cases can create a non-functional protein, given that, according to [@B17], this tumor suppressor gene presents very unusual characteristics. As opposed to the majority of tumor suppressor genes, the loss of just a single allele results in an abnormal phenotype, i.e., it is considered a haploinsufficient suppressor and, as a result, does not follow the classical genetic model of biallelic inactivation. The loss of activity of this protein seems to be common in different types of cancer ([@B16]) and explains our findings.

Several studies have demonstrated that tumors with extracapsular extension had a higher risk of progression than those confined to the prostate and this can be considered an indicator of poor prognosis ([@B42]; [@B8]). [@B42] reported that a PTEN deletion was significantly associated with higher extracapsular extension. Our results, added to these, suggest that alterations in this gene have the ability to predict aggressive disease.

The gene *AKT1* belongs to the *AKT* family and the protein that it codes plays an important role in cellular survival via apoptosis control; it is related to the development of various diseases, including cancer ([@B32]). The relationship between PCa and rs2494750SNP is controversial. Karyadi *et al.* (2015) and [@B11] associated this SNP with death specifically for PCa patients carrying allele G. Nonetheless, this SNP, in the present study, protected the carriers of the CG genotypes against PCa. The heterozygous genotype, when combined with the A allele of the (rs17302090) *AR* gene, also protects against PCa. Other research has failed to associate the (rs2494750) *AKT1* gene with squamous cell carcinoma of the esophagus ([@B50]) or with cancer of the endometrium ([@B9]). Given these conflicting results, it would be interesting to investigate this question further with larger samples of PCa patients from other populations.

Studies, both *in vitro* and *in vivo*, have demonstrated that PI3K/AKT/mTOR signaling interacts with the *AR* gene in an antagonistic manner; when the pathway is inhibited, it increases expression of AR, and as such could serve as a therapeutic target for patients with androgen-dependent prostate cancer ([@B21]). According to these authors, it appears that the *AR* gene signaling pathway, depending on downstream genes, could be involved in the malignant transformation of PCa.

Some of the SNPs studied in the *AR* gene have already demonstrated that the coded protein changes binding with cofactors. This change is associated with androgen insensitivity syndrome, which can affect the activity and level of circulating androgens ([@B30]). In our study, the rs17302090 SNP was not associated with PCa. [@B40] evaluated the rs1204038, which presents strong linkage disequilibrium with rs17302090, evaluated in this study, and did not identify any association between risk of aggressive PCa and androgen deprivation therapy. On the other hand, [@B26] demonstrated that carriers of the rare allele A (rs17302090) who received primary hormonal therapy presented twice the risk of death from PCa compared to individuals that had the prevalent allele. The authors further suggested that this polymorphism would act as a modifier in the hormonal treatment of the disease leading to death by PCa.

Nonetheless, allele A of the *AR* gene, when combined with the gene *AKT1* (CC), conferred protection against seminal vesicle invasion and tumor bilaterality; when combined with the gene *PI3K* (GG), it also conferred protection against tumor bilaterality. The finding of seminal vesicle invasion at the time of radical prostatectomy is an adverse pathologic finding that confers a decrease in long-term freedom from biochemical recurrence, exceeded in magnitude only by the finding of lymph node metastases ([@B33]).

The last gene evaluated in this study codes the enzyme AMACR, which is overexpressed in prostate tumor tissue. This overexpression seems to be involved in carcinoma initiation, as this type of alteration has been described in prostatic intraepithelial neoplasia ([@B18]; [@B19]). The enzyme AMACR participates in the metabolism of fatty acids. The main dietary source of branched-chain fatty acids in the human diet includes red meat, which is considered a PCa risk factor. The consumption of these fatty acids is associated with the overexpression of *AMACR* in cancerous prostate cells, as it consistently increases oxidation in these cells, resulting in the production of reactive oxygen species that can damage DNA ([@B48]).

The rs3195676 SNP, located on exon 1 in a coding region, results in the substitution of valine for methionine. The use of bioinformatics tools to predict the influence of this exchange of amino acids on protein integrity has demonstrated that this substitution is not tolerated in carriers of recessive alleles of this SNP, suggesting that this results in protein damage and lower expression ([@B24]).

[@B23] studied this polymorphism and demonstrated that male carriers of allele G with a Gleason score ≥ 7 and ≥ pT2c present a greater risk of developing PCa. An *in vitro* experiment also demonstrated that a decrease in the level of AMACR protein results in a decrease in the proliferation of prostate adenocarcinoma cells ([@B49]). This explains the results obtained herein, given that whenever the A allele of the SNP was present, it provided protection against more aggressive PCa - the AMACR protein was damaged and likely less expressed, improving the prognosis for the patient carriers of the rare allelei n relation to seminal vesicle invasion. Genotypes of the AMACR gene (GA/GA+AA) alone or in combination with the AKT1 gene (CC) significantly protected the occurrence of seminal vesicle invasion.

The *AKT1* and *AR* genes, alone or combined, showed protection for PCa, while *AKT1, PI3K, AR*, and *AMACR* genes protected against PCa aggressiveness. Only the *PTEN* gene associated with *AMACR* or *AR* indicated a risk for extracapsular extension. These results, showing the influence of the SNPs assessed on the clinical and pathological outcomes of PCa, are summarized in [Figure 1](#f1){ref-type="fig"}.

![An individual\'s genetic profile can: (A) Identify men with genotypes that confer protection for prostate cancer. (B) Discriminate men with a better or worse prognosis for prostate cancer.](1415-4757-GMB-43-3-e20180329-gf01){#f1}

The identification and implementation of novel molecular markers to improve the prediction of tumor behavior in patients with PCa will reduce the variability among observers regarding the distinction of many histopathological parameters. This is important for treatment decisions that depend heavily on the opinions of an individual pathologist ([@B15]). The results of our study indicate SNPs as potential molecular markers to be used in prognostic panels for PCa, however, these findings still need additional confirmation before use in clinical practice.
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